SNV4818

Phase 2Small molecule

PPikavation Therapeutics, Inc.

SNV4818 is one of 47 small molecule programs targeting Advanced Solid Tumors. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Solid TumorsRecruiting

Advanced Solid TumorsPhase 2

Recruiting

Competition

Competitive Landscape

286 competitors in Advanced Solid Tumors

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

47 2

Taxol

Teva

Phase 2

24 3

Opdivo

Bristol-Myers Squibb

Phase 2

18 4

Paraplatin

AAvyxa

Phase 2

31 5

Tecentriq

Roche

Phase 2

11 6

Taxotere

AAvyxa

Phase 2

23 7

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

19 8

Braftovi

Pfizer

Phase 2

4 9

Erbitux

Sutent

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1/2Recruiting

Advanced Solid Tumors

NCT06736704

Clinical

Trials by Indication[1]

Advanced Solid Tumors1 trial

SNV4818 in Participants With Advanced Solid Tumors

Recruiting·PPikavation Therapeutics, Inc.·Phase 1/2·NCT06736704·320 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SNV4818. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SNV4818 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SNV4818. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pikavation Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPikavation Therapeutics, Inc.

SNV4818

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Advanced Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News